Comprehensive analysis of the relationship between cuproptosis-related genes and esophageal cancer prognosis

Table 2 Relationship between the clinicopathological characteristics and survival outcome

Parameters	Overall survival			Progression-free survival
	Non-event	Event	P value	Non-event	Event	P value
Age, yr			0.758			0.628
≤ 65	57	37		50	44
> 65	36	21		28	29
Sex			0.102			0.009
Female	17	5		17	5
Male	76	53		61	68
AJCC-TNM stage			0.021			0.013
I and II	61	27		53	35
III and IV	32	31		25	38
Pathological type			0.011			0.469
Adenocarcinoma	38	36		36	38
SCC	55	22		42	35
EGFR status						0.596
Wild-type	3	2	0.941	2	3
Mutant	90	56		76	70
BRAF status			0.428			0.332
Wild-type	1	0		1	0
Mutant	92	58		77	73
KRAS status			0.734			0.962
Wild-type	1	1		1	1
Mutant	92	57		77	72
PIK3CA status			0.828			0.896
Wild-type	9	5		7	7
Mutant	84	53		71	66

AJCC: American Joint Committee on Cancer; BRAF: v-Raf murine sarcoma viral oncogene homolog B1 genes; EGFR: Epidermal growth factor receptor; KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; PIK3CA: Phosphatidylino-sitol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; SCC: Squamous cell carcinoma; TNM: Tumor-node-metastasis.